Share on StockTwits

MedAssets (NASDAQ:MDAS) Director Terrence J. Mulligan sold 1,000 shares of the company’s stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $21.97, for a total value of $21,970.00. Following the sale, the director now directly owns 927 shares in the company, valued at approximately $20,366. The sale was disclosed in a legal filing with the SEC, which is available at this link.

MDAS has been the subject of a number of recent research reports. Analysts at Citigroup Inc. downgraded shares of MedAssets from a “buy” rating to a “neutral” rating in a research note on Thursday, May 29th. They now have a $26.00 price target on the stock, down previously from $28.00. Separately, analysts at Bank of America downgraded shares of MedAssets from a “buy” rating to a “neutral” rating in a research note on Thursday, May 22nd. They now have a $24.00 price target on the stock, down previously from $25.00. Finally, analysts at Stephens initiated coverage on shares of MedAssets in a research note on Tuesday, May 20th. They set an “equal weight” rating and a $20.00 price target on the stock. Twelve research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. MedAssets presently has a consensus rating of “Hold” and an average price target of $25.28.

MedAssets (NASDAQ:MDAS) opened at 22.14 on Tuesday. MedAssets has a 1-year low of $19.33 and a 1-year high of $26.58. The stock’s 50-day moving average is $23.14 and its 200-day moving average is $22.88. The company has a market cap of $1.350 billion and a price-to-earnings ratio of 50.61.

MedAssets (NASDAQ:MDAS) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.32 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.33 by $0.01. Analysts expect that MedAssets will post $1.37 EPS for the current fiscal year.

MedAssets, Inc (NASDAQ:MDAS) provides technology-enabled products and services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.